Capricor Therapeutics
CAPR
75 hedge funds and large institutions have $127M invested in Capricor Therapeutics in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 14 closing their positions.
315% more capital invested
Capital invested by funds: $30.7M → $127M (+$96.6M)
100% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 14
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
46% more call options, than puts
Call options by funds: $33.4M | Put options by funds: $22.9M
23% more funds holding
Funds holding: 61 → 75 (+14)
5.63% more ownership
Funds ownership: 20.1% → 25.72% (+5.6%)
Top Buyers
| 1 |
SCM
Superstring Capital Management
New York
|
+$1.67M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.48M |
| 3 |
ACM
Altium Capital Management
New York
|
+$1.41M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.24M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$756K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$1.9M |
| 2 |
Renaissance Technologies
New York
|
-$656K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$426K |
| 4 |
Man Group
London,
United Kingdom
|
-$404K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$331K |
CAPR Hedge Fund Activity: Q3 2024 in Review
75 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2024, worth a combined $127M — up 315% from $30.7M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CAPR positions and 14 closed out — a net gain of 14 holders — while 22 added to existing stakes and 12 trimmed.
The largest buyer was Superstring Capital Management, opening a new position worth an estimated $1.67M. The largest seller was Millennium Management, cutting an estimated $1.9M.
- 75 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2024, up from 61 in Q2 2024.
- Funds reported $127M of Capricor Therapeutics stock for Q3 2024, up 315% quarter-over-quarter.
- 28 funds opened new Capricor Therapeutics positions in Q3 2024 and 14 closed out, a net change of +14 holders.
- The largest Capricor Therapeutics buyer in Q3 2024 was Superstring Capital Management, an estimated $1.67M added.
- The largest Capricor Therapeutics seller in Q3 2024 was Millennium Management, an estimated $1.9M sold.
Based on aggregated 13F filings for Q3 2024.